SUZANNE BIERMAN, JD, MPH Administrator



## DEPARTMENT OF HEALTH AND HUMAN SERVICES DIVISION OF HEALTH CARE FINANCING AND POLICY 1100 East William Street, Suite 101 Carson City, Nevada 89701 Telephone (775) 684-3676 • Fax (775) 687-3893 <u>http://dhcfp.nv.gov</u>

## NOTICE OF MEETING TO SOLICIT PUBLIC COMMENTS AND INTENT TO ACT UPON AMENDMENTS TO THE NEVADA MEDICAID SERVICES MANUALS (MSM)

## AGENDA

Date of Publication: Date of Revision:	April 19, 2019 May 15, 2019
Date and Time of Meeting:	May 23, 2019 at 9:00 AM
Name of Organization:	The State of Nevada, Department of Health and Human Services (DHHS), Division of Health Care Financing and Policy (DHCFP)
Place of Meeting:	Division of Public and Behavioral Health 4150 Technology Way, Room 303 Carson City, Nevada 89706
Place of Videoconference	Grant Sawyer Office Building 555 E. Washington Avenue, Suite 5100 Las Vegas, Nevada 89101
Teleconference:	(888) 363-4735
Access Code:	1961395

## AGENDA

- 1. General Public Comments (Because of time considerations, the period for public comment by each speaker or organization may be limited to three minutes and speakers are urged to avoid repetition of comments made by previous speakers.)
- 2. For possible action: Discussion and adoption of changes to MSM Chapter 1200 Prescribed Drugs

Nevada Department of Health and Human Services Helping People – It's Who We Are and What We Do The DHCFP proposes revisions to MSM Chapter 1200, Appendix A based on recommendations approved at the October 18, 2018 Drug Use Review (DUR) meeting. The recommended changes include the addition of Ilumya® (tildrakizumab), Inflectra® (infliximab), Olumiant® (baricitinib), Otezla® (apremilast), Renflexis® (infliximab) and Taltz® (ixekizumab) to the existing prior authorization criteria for Immunomodulator Medications. The addition of Calcitonin Gene-Related Peptide (CGRP) Receptor Inhibitor to the existing Anti-Migraine Medications prior authorization criteria. The addition of Opioids Prescribed to Under Age 18 to the existing Opioid prior authorization criteria.

Providers who prescribe, dispense or administer these drugs may be affected by this change, including but not limited to the following provider types (PTs): Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and Long Term Acute Care (LTAC) Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); Critical Access Hospital (CAH), Inpatient (PT 75); Audiologist (PT 76); Physician's Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: There is no financial impact on local government.

Effective date: June 3, 2019

- a. Presentation of MSM Chapter 1200
- b. Public comment on proposed changes
- c. Adoption of proposed changes
- 3. For possible action: Discussion and adoption of changes to MSM Chapter 1200 Prescribed Drugs

The DHCFP proposes revisions to MSM Chapter 1200, Appendix A based on recommendations approved at the January 24, 2019 DUR meeting. The recommended changes include the addition of prior authorization criteria for short acting beta agonists, new criteria for Epidiolex®, revised criteria for compounded medications and new criteria for oral oncology medications and pulmonary arterial hypertension agents.

Providers who prescribe, dispense or administer these drugs may be affected by this change, including but not limited to the following PTs: Outpatient Surgery (PT 10); Hospital, Inpatient (PT 11); Hospital, Outpatient (PT 12); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Public (PT 16); Special

Clinics (PT 17); Nursing Facility (PT 19); Physician/Osteopath (PT 20); Podiatrist (PT 21); Advanced Practice Registered Nurse (PT 24); Pharmacy (PT 28); Home Health Agency (PT 29); Ambulatory Surgical Centers, Freestanding (PT 46); Indian Health Programs and Tribal Clinics (PT 47); Indian Health Service Hospital, Inpatient (Tribal) (PT 51), Indian Health Service Hospital, Outpatient (Tribal) (PT 52); Transitional Rehabilitative Center, Outpatient (PT 55); Inpatient Rehabilitation and LTAC Specialty Hospitals (PT 56); Hospice (PT 64); Hospice, Long Term Care (PT 65); Intermediate Care Facilities for Individuals with Intellectual Disabilities, Private (PT 68); Nurse Anesthetist (PT 72); CAH, Inpatient (PT 75); Audiologist (PT 76); Physician's Assistant (PT 77); Indian Health Service Hospital, Inpatient (Non-Tribal) (PT 78); Indian Health Service Hospital, Outpatient (Non-Tribal) (PT 79).

Financial impact on local government: There is no financial impact on local government.

Effective date: June 3, 2019

- a. Presentation of MSM Chapter 1200
- b. Public comment on proposed changes
- c. Adoption of proposed changes
- 4. Adjournment

Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.

<u>PLEASE NOTE</u>: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to three minutes.

This notice and agenda have been posted at <u>http://dhcfp.nv.gov/</u> and <u>notice.nv.gov/</u>.

Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHCFP website <u>http://dhcfp.nv.gov/</u>. The agenda posting of this meeting can be viewed at the following locations: Carson City Central Office; Las Vegas District Office; Reno District Office and Elko District Office and may be reviewed during normal business hours.

If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to Ellen Flowers at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, Nevada 89701.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail

at: <u>eflowers@dhcfp.nv.gov</u>, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Ellen Flowers at (775) 684-3684.